Clinical Studies of Lactoferrin in Neonates and Infants: An Update

Paolo Manzoni, MD, PhD

Senior Faculty, Neonatology and Neonatal Intensive Care Unit,
Sant’Anna Hospital,
Torino, Italy
Rate this Content 0 Votes

Speaker Bio - Paolo Manzoni, MD, PhD

Dr. Manzoni earned his MD and specialization in Pediatrics from the University of Torino School of Medicine. He conducted his residency in Pediatric Pulmonology and a fellowship in Infectious Diseases and Immunology at Azienda Ospedaliera OIRM –Sant’Anna of Torino. He is currently a member of the Faculty Staff of the Division of Neonatology and Neonatal Intensive Care Unit (NICU) at Sant’Anna Hospital.

Dr. Manzoni’s primary research interests include pediatric and neonatal infectious diseases, fungal infections and prevention, human milk bioactive nutrients, respiratory syncytial virus (RSV)–related diseases, retinopathy of prematurity, and neonatal nutrition. He was the leading investigator of the first multicenter clinical trial of prophylactic fluconazole in preterm neonates and led the first international, multicenter clinical trial of probiotic and lactoferrin feeding in preterm neonates. Dr. Manzoni is currently involved in several European Union–funded research consortiums devoted to the study of antimicrobial drugs for neonates (eg, NeoMero, NeoVanc). He is the author of approximately 180 research articles published in peer-reviewed Italian and international medical journals and serves on the editorial boards of a number of peer-reviewed, leading international journals.

Dr. Manzoni is an associate member of the American Society for Pediatric Research and the Italian Society of Neonatology and Pediatrics and serves as an external consultant for the Italian Drug Agency and the European Medicines Agency. He is co-founder of the Charity and Scientific Foundation Crescere insieme al Sant’Anna, and in 2014 he helped establish the RSV Network (ReSViNET) to help improve RSV research and foster global collaboration.